AKBA compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

AKBAAkebia Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

AKBAAkebia Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AKBA

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±33.6%▼−38.75%×1.15

Q2 FY26±35.9%▼−26.02%×0.72

May 7 '26±14.2%▼−20.27%×1.43

Q1 FY26±27.1%▲+9.09%×0.34

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedAKBA realized, solidLLY realized, hatchedOne scale, both sides: full bar = 39%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

AKBAAkebia Therapeutics, Inc.

0.39▼−8.23%

Mkt cap$118.1MRevenue$37MQ3 FY26Revenue$236MFY25

LLYELI Lilly & Co

1,364.14▼−0.04%

Regular sessionNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Regular sessionNov 6 '26

AKBAAkebia Therapeutics, Inc.

LLYELI Lilly & Co

0.39▼−8.23%

Price

1,364.14▼−0.04%

$118.1M

Mkt cap

$1.2T

Q3 FY26$37M

Revenue

$24.4BQ3 FY26

FY25$236M

Revenue

$65.2BFY25

AKBA0.39▼−8.23%vsLLY1,364.14▼−0.04%Regular sessionNov 6 '26